According to the FDA label, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior serious hypersensitivity to semaglutide
Most high-quality research shows clear differences in average weight loss: Tirzepatide (Zepbound) In large clinical trials (SURMOUNT-1), tirzepatide produced 15% to 22.5% total body weight loss , depending on the dose4
At-Home Screening Fill out your medical profile and be guided through a simple, at-home blood collection
Fecal menaquinone profiles of overweight adults are associated with gut microbiota composition during a gut microbiota-targeted dietary intervention
Variations in inflammatory mediators were monitored by serum CRP and erythrocyte sedimentation rate (ESR) as principal outcomes at baseline and 7th day
These medications work by mimicking natural hormones that regulate appetite and blood glucose levels